US stock · Healthcare sector · Drug Manufacturers—Specialty & Generic
Company Logo

Catalent, Inc.

CTLTNYSE

101.38

USD
+4.69
(+4.85%)
Market Open
34.93P/E
24Forward P/E
1.35P/E to S&P500
18.169BMarket CAP
- -Div Yield
Upcoming Earnings
3 May
Shares Short
5/13/22
3.67M
Short % of Float
2.61%
Short % of Shares Outs.
2.05%
% Held by Insiders
0.25%
% Held by Institutions
101.54%
Beta
1.38
PEG Ratio
1.63
52w. high/low
142.64/86.34
Avg. Daily Volume
1.28M
Return %
Stock
S&P 500
1 year
(7.23)
(6.01)
3 years
107.85
39.24
5 years
170.46
63.25
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
30.18
19.30
34.41
23.63
32.24
18.92
43.39
25.51
47.87
29.23
58.38
29.29
120.48
31.04
142.64
97.86
128.26
86.34
Currency: USD
- -
- -
- -
- -
- -
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
- -
- -
- -
- -
- -
13.06
14.45
15.35
15.58
15.27
14.81
16.60
18.78
17.46
20.66
23.80
26.99
Earnings per share
- -
- -
- -
- -
- -
(0.46)
(0.21)
(0.40)
0.14
1.77
0.89
0.88
0.64
0.92
1.47
3.48
2.78
FCF per share
- -
- -
- -
- -
- -
0.11
(0.14)
0.13
0.48
0.26
0.13
1.28
1.51
0.21
(0.17)
(1.51)
(0.63)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.24
0.13
0.05
CAPEX per share
- -
- -
- -
- -
- -
0.74
0.89
1.04
1.04
1.18
1.12
1.12
1.35
1.51
3.11
4.08
3.52
Book Value per sh.
- -
- -
- -
- -
- -
- -
(2.99)
(3.50)
(3.16)
5.29
5.10
5.79
8.28
11.66
23.40
25.44
25.49
Comm.Shares outs.
- -
- -
- -
- -
- -
117
117
117
117
120
125
125
131
144
150
168
174
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
- -
172.3
16.2
28.0
39.5
64.5
51.5
51.9
34.0
34.9
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
- -
9.5
0.8
1.3
1.7
2.6
2.1
1.4
1.1
1.3
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.3%
0.1%
0.0%
Revenue (m)
- -
- -
- -
- -
- -
1,532
1,695
1,800
1,828
1,831
1,848
2,075
2,463
2,518
3,094
3,998
4,703
Operating margin
- -
- -
- -
- -
- -
12.1%
11.7%
11.4%
13.2%
14.2%
11.8%
11.3%
11.0%
10.9%
12.7%
20.7%
16.1%
Depreciation (m)
- -
- -
- -
- -
- -
116
130
152
143
141
141
147
190
229
254
289
351
Net profit (m)
- -
- -
- -
- -
- -
(54)
(24)
(47)
16
212
112
110
84
132
221
585
513
Income tax rate
- -
- -
- -
- -
- -
(438.9)%
2.7%
(100.8)%
73.4%
(86.8)%
23.3%
19.0%
45.0%
14.3%
15.2%
18.2%
15.7%
Net profit margin
- -
- -
- -
- -
- -
(3.5)%
(1.4)%
(2.6)%
0.9%
11.6%
6.0%
5.3%
3.4%
5.2%
7.1%
14.6%
10.9%
Working capital (m)
- -
- -
- -
- -
- -
- -
265
268
235
339
399
591
663
725
1,400
1,722
1,979
Long-term debt (m)
- -
- -
- -
- -
- -
- -
2,640
2,657
2,685
1,864
1,833
2,055
2,649
2,883
2,945
3,166
4,157
Equity (m)
- -
- -
- -
- -
- -
- -
(351)
(411)
(371)
634
636
724
1,087
1,682
3,505
4,274
4,632
ROIC
- -
- -
- -
- -
- -
- -
5.7%
13.7%
2.3%
14.9%
6.6%
6.1%
3.7%
4.1%
4.8%
8.5%
6.7%
Return on capital
- -
- -
- -
- -
- -
- -
5.1%
5.9%
7.4%
7.0%
7.6%
6.5%
5.8%
4.3%
5.0%
9.1%
7.2%
Return on equity
- -
- -
- -
- -
- -
- -
7.0%
11.4%
(4.4)%
33.5%
17.5%
15.2%
7.7%
7.8%
6.3%
13.7%
11.1%
Plowback ratio
- -
- -
- -
- -
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
83.6%
96.2%
98.4%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
(0.4)%
(3,047.1)%
- -
- -
(140.3)%
(1,505.1)%
3,962.0%
23.7%
(7.4)%
Capital Structure
3 May · 2022 | Q3
All numbers in millions
Total liabilities
$ 5,690
Total assets
$ 10,322
Long-term debt
$ 4,157
Cash and equiv.
$ 786
Goodwill
$ 3,012
Retained earnings
$ 350
Common stock
180
Enterprise Value
$ 21,540
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
345
953
967
Receivables
733
919
1,243
Inventory
265
347
593
Other
52
682
666
Current assets
1,396
2,293
2,918
Acc. Payable
256
321
385
Debt due
77
73
91
Other
338
499
720
Current liabilities
671
893
1,196
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
29.21%
18.25%
10.46%
Cash flow
892.16%
161.24%
171.41%
Earnings
165.07%
66.57%
153.77%
Dividends
(39.23)%
- -
- -
Book value
21.93%
58.83%
(1.54)%
Insider Trading
Type
Shares
Date
Zippelius Peter
Sale
487,092
02/06/22
Hopson Ricky
Sale
2,325
01/31/22
Whitlow Ricci S
Sale
184
01/21/22
Flynn Karen
Sale
2,472
01/10/22
Arnold Jonathan
Award
4,017
01/03/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
665
721
761
948
3,094
2021
846
911
1,053
1,188
3,998
2022
1,025
1,217
1,273
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
0.30
0.14
1.03
1.47
2021
0.49
0.53
1.38
1.09
3.48
2022
0.54
0.55
0.78
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.08
0.05
0.05
0.05
0.24
2021
0.05
0.03
0.03
0.03
0.13
2022
0.02
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—Specialty & Generic
CEO:
Mr. John Chiminski
Full-time employees:
17,300
City:
Somerset
Address:
14 Schoolhouse Rd
IPO:
Jul 31, 2014
Website:
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Recent News